|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2008
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension
1 Experimental Medicine and Toxicology, Imperial College London, Hammersmith Hospital, London, UK, 2 Medical Clinic II/V, Dept of Internal Medicine, University Hospital Giessen and Marburg, Giessen, Germany.
CORRESPONDENCE: M. R. Wilkins, Experimental Medicine and Toxicology, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. Fax: 44 2083831963. E-mail: m.wilkins{at}imperial.ac.uk
Keywords: Cyclic guanosine monophosphate, hypertension, phosphodiesterase inhibition, pulmonary
Received: September 20, 2007
Accepted March 10, 2008
The pulmonary vascular bed is both a source of and target for a number of vasoactive factors. Among the most important for pulmonary vascular homeostasis are factors that utilise cyclic guanosine monophosphate (cGMP) as an intracellular second messenger. These include nitric oxide and the natriuretic peptide family (atrial, brain and C-type natriuretic peptides). In the search for therapeutic strategies that engage the cGMP signalling pathway for the treatment of pulmonary arterial hypertension (PAH), inhibition of cGMP metabolism by phosphodiesterase type 5 (PDE5)-targeted compounds has proven most successful to date. One PDE5 inhibitor, sildenafil, has been shown to improve pulmonary haemodynamics and exercise capacity in patients with PAH and is now an approved treatment. Others are under investigation.
An interesting, although still tentative, observation is the potential of sildenafil to reduce pulmonary vascular resistance without adversely affecting ventilation–perfusion matching. Another is the expression of phosphodiesterase type 5 in the hypertrophied right ventricle. These data suggest that phosphodiesterase type 5 inhibitors may have effects that distinguish them from other treatments for pulmonary hypertension and merit further study.
This article has been cited by other articles:
|
|
 |
|
  M. M. Hoeper The new definition of pulmonary hypertension Eur. Respir. J., October 1, 2009; 34(4): 790 - 791. [Full Text] [PDF]
|
|
|
|
 |
|
 Z-C Jing, X Jiang, B-X Wu, X-Q Xu, Y Wu, C-R Ma, Y Wang, Y-J Yang, J-L Pu, and W Gao Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study Heart, September 15, 2009; 95(18): 1531 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Peacock, R. Naeije, N. Galie, and L. Rubin End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur. Respir. J., July 1, 2009; 34(1): 231 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Spiekermann, K. Schenk, and M. M. Hoeper Increased xanthine oxidase activity in idiopathic pulmonary arterial hypertension Eur. Respir. J., July 1, 2009; 34(1): 276 - 276. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, H. Gall, H. J. Seyfarth, M. Halank, H. A. Ghofrani, J. Winkler, H. Golpon, K. M. Olsson, N. Nickel, C. Opitz, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Eur. Respir. J., July 1, 2009; 34(1): 132 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper, J. A. Barbera, R. N. Channick, P. M. Hassoun, I. M. Lang, A. Manes, F. J. Martinez, R. Naeije, H. Olschewski, J. Pepke-Zaba, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S85 - S96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Opitz and L. J. Rubin Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer? Eur. Respir. J., June 1, 2009; 33(6): 1247 - 1249. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, K. M. Olsson, A. Schneider, and H. Golpon Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy Eur. Respir. J., June 1, 2009; 33(6): 1518 - 1519. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Faughnan, J. T. Granton, and L. H. Young The pulmonary vascular complications of hereditary haemorrhagic telangiectasia Eur. Respir. J., May 1, 2009; 33(5): 1186 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Humbert More pressure on pulmonary hypertension Eur. Respir. Rev., March 1, 2009; 18(111): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
H. A. Ghofrani and F. Grimminger Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Eur. Respir. Rev., March 1, 2009; 18(111): 35 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chaouat, R. Naeije, and E. Weitzenblum Pulmonary hypertension in COPD Eur. Respir. J., November 1, 2008; 32(5): 1371 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper Treating pulmonary hypertension in COPD: where do we start? Eur. Respir. J., September 1, 2008; 32(3): 541 - 542. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |